​

Adial Pharmaceuticals Stock (NASDAQ:ADIL)

OwnershipFinancialsChart
Adial Pharmaceuticals by TradingView

Previous Close

$1.97

52W Range

$1.54 - $30.25

50D Avg

$4.13

200D Avg

$8.16

Market Cap

$1.79M

Avg Vol (3M)

$72.83K

Beta

1.32

Div Yield

-

ADIL Company Profile

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

5

IPO Date

Jul 27, 2018

Website

ADIL Performance

ADIL Financial Summary

Dec 25Dec 24Dec 23
Revenue---
Operating Income$-7.80M$-8.28M$-6.89M
Net Income$-7.98M$-13.20M$-7.00M
EBITDA$-7.80M$-8.28M$-7.00M
Basic EPS$-11.93$-17.75$-136.00
Diluted EPS$-11.93$-17.75$-136.00

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

TickerCompany
CELZCreative Medical Technology Holdings, Inc.
HCWBHCW Biologics Inc.
NRSNNeuroSense Therapeutics Ltd.
ACXPAcurx Pharmaceuticals, Inc.
KPRXKiora Pharmaceuticals, Inc.
BCLIBrainstorm Cell Therapeutics Inc.
APREAprea Therapeutics, Inc.
BCDABioCardia, Inc.
CDIOCardio Diagnostics Holdings, Inc.